Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Ended earlyNCT04683939
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Who this might be right for
Solid TumorGastric CancerGastroesophageal Junction Adenocarcinoma+5 more
BioNTech SE 13
Testing effectiveness (Phase 2)Study completedNCT01630083
What this trial is testing

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc. 252
Large-scale testing (Phase 3)Looking for participantsNCT07284134
What this trial is testing

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 560
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795346
What this trial is testing

ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 380
Large-scale testing (Phase 3)Active Not RecruitingNCT06351020
What this trial is testing

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Zhejiang Co., Ltd. 387
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Not applicableLooking for participantsNCT07427992
What this trial is testing

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
European Institute of Oncology 70
Early research (Phase 1)Ended earlyNCT04260191
What this trial is testing

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric and Gastroesophageal Junction Adenocarcinoma
Amgen 15
Testing effectiveness (Phase 2)Looking for participantsNCT07569068
What this trial is testing

Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 88
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06881017
What this trial is testing

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Who this might be right for
Gastric CancerHER2 + Gastric CancerCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction+1 more
China Medical University, China 140
Early research (Phase 1)Study completedNCT01671774
What this trial is testing

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Gastric AdenocarcinomaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of Esophagus
Astellas Pharma Global Development, Inc. 29
Testing effectiveness (Phase 2)Looking for participantsNCT07432295
What this trial is testing

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Who this might be right for
Solid TumorAdvanced CancerMetastatic Cancer+3 more
I-Mab Biopharma US Limited 180
Large-scale testing (Phase 3)Looking for participantsNCT07385703
What this trial is testing

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. 752
Early research (Phase 1)Study completedNCT04400383
What this trial is testing

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Solid TumorGastric CancerPancreatic Adenocarcinoma
CARsgen Therapeutics Co., Ltd. 62
Testing effectiveness (Phase 2)Looking for participantsNCT07556640
What this trial is testing

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Who this might be right for
Gastric Cancer Stage IVPeritoneal Metastases From Gastric CancerGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 74
Testing effectiveness (Phase 2)Looking for participantsNCT06962137
What this trial is testing

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven 100
Testing effectiveness (Phase 2)Looking for participantsNCT07483554
What this trial is testing

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Who this might be right for
CLDN18.2 PositiveGastric/Gastroesophageal Junction AdenocarcinomaPancreatic Ductal Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 389
Testing effectiveness (Phase 2)Looking for participantsNCT07622940
What this trial is testing

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Who this might be right for
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech 36
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Next Page